Patient Access to Miltefosine in Developing Countries Not Secure Despite Award of US FDA Priority Review Voucher Sold for USD 125 Million
November 25, 2014
November 25, 2014
GENEVA, Nov. 25 -- The Drugs for Neglected Diseases Initiative issued the following news release:
Knight Therapeutics has landed a USD 125 million windfall after selling its Priority Review Voucher (PRV) granted for the registration of miltefosine (Impavido), even while access to the life-saving drug remains unsecured. The Drugs for Neglected Diseases initiative (DNDi) and Medecins Sans Frontieres Access Campaign (MSF) are urging the drug's license-holders and manufacturers - Knig . . .
Knight Therapeutics has landed a USD 125 million windfall after selling its Priority Review Voucher (PRV) granted for the registration of miltefosine (Impavido), even while access to the life-saving drug remains unsecured. The Drugs for Neglected Diseases initiative (DNDi) and Medecins Sans Frontieres Access Campaign (MSF) are urging the drug's license-holders and manufacturers - Knig . . .